By CleopatraRX | Medically Reviewed by Manasa Murthy, PharmD | Updated June 2026
Key Takeaways
- “Estrogen” is not one hormone. It is a class of hormones — and estradiol and estriol bind to different receptors, with meaningfully different effects in the body.
- Estradiol binds primarily to estrogen receptor alpha (ERα), which is concentrated in breast and reproductive tissue. It has been the default hormone therapy in the United States for decades.
- Estriol binds preferentially to estrogen receptor beta (ERβ), which is enriched in the hippocampus, cerebral cortex, and other regions responsible for memory, processing speed, and executive function.
- Estriol has been used safely in Europe and Asia — both orally and topically — for more than 40 years. In the United States, it has never received FDA approval and remains available only through compounding pharmacies.
- The reason most doctors haven’t discussed estriol with you is not indifference. The research specifically connecting estriol to cognitive protection is recent — and it required a neurologist willing to spend thirty years following a signal the pharmaceutical industry wouldn’t fund.
- PearlPAK® by CleopatraRX is a compounded oral estriol and progesterone protocol developed from Dr. Rhonda Voskuhl’s NIH-funded research at UCLA. It is designed for women whose primary concern is cognitive health during perimenopause or menopause.
The Question Women Are Starting to Ask
If you have been on estradiol, a patch, a pill, a gel and your hot flashes improved but your brain didn’t, keep reading.
Estradiol is effective for vasomotor symptoms. It is FDA-approved, widely prescribed, and well-studied for sleep, bone density, and genitourinary health. But it was not designed for the brain. And for women whose most pressing symptom is cognitive — the word-finding gaps, the processing slowdowns, the feeling that their thinking has become unreliable — estradiol may not be the right tool.
The question worth asking is not whether hormone therapy works. It is which hormone, binding which receptor, for which purpose.
TWO MINUTES · NO COST
It's not just stress.
There's a way to measure it.
The Menopause Cognitive Health Assessment was built to detect the early cognitive changes from menopause. Two minutes, real results.
“Estrogen” comes in more than one form
There are three naturally occurring estrogens: estrone (E1), estradiol (E2), and estriol (E3). Each has a distinct chemical structure. Each binds to estrogen receptors differently. And the effects of that binding depend entirely on which receptor is activated and where in the body that receptor lives.
The two primary estrogen receptors are:
- Estrogen receptor alpha (ERα): Concentrated in breast tissue, the uterus, and reproductive organs. Estradiol binds strongly here. ERα is the receptor responsible for estradiol’s well-known effects on bone density, hot flashes, and reproductive tissue.
- Estrogen receptor beta (ERβ): Enriched in the hippocampus, cerebral cortex, basal forebrain, and other regions responsible for memory, processing speed, and executive function. These are the same regions that show measurable atrophy on MRI in menopausal women with untreated cognitive symptoms.[1] Estriol binds preferentially here.
Calling estriol “weaker” because it binds less aggressively to ERα is a category error. It binds differently, to a different receptor, in a different tissue, for a different purpose. The question is not potency, but specificity.
Why Estriol Has Been Overlooked in the United States
Estriol has been used in Europe and Asia for more than forty years in both topical and oral formulations. Approved products like Ovestin have been available across Europe for decades.
In the United States, that path never happened.
Estriol has never received FDA approval. It is available only through compounding pharmacies, which means it has never had the pharmaceutical industry backing required to fund large-scale clinical trials, achieve formulary coverage, or reach the prescribing mainstream. Without approval, there is no marketing. Without marketing, most clinicians never encounter it in their training or their continuing education.
The “weaker estrogen” label compounded the problem. Early comparative studies measured estrogen activity at ERα receptors, where estradiol binds and therefore estriol was viewed as less potent.
That changed because of one researcher who was paying attention to her MS patients during pregnancy.
The Discovery: From MS to Menopause
Dr. Rhonda Voskuhl is a Professor of Neurology at UCLA with thirty years of NIH-funded research studying the female brain. Her path to estriol began not with menopause, but with multiple sclerosis.
Women with MS experience a striking reduction in disease relapses during pregnancy — up to 70% fewer — and a sharp increase after delivery.[2] The question Dr. Voskuhl spent years pursuing was why?
Pregnancy produces three estrogens. Two of them are estradiol and progesterone and are present throughout the menstrual cycle. The third — estriol — is unique to pregnancy. Levels can reach 1,000 times higher than baseline. Dr. Voskuhl followed that signal.
In mouse models of MS, she mapped how estriol binding through ERβ was neuroprotective — which cells it bound to, how it triggered repair, what the mechanism looked like at the molecular level.[3] She then ran three clinical trials in MS patients treated with oral estriol. The findings were consistent: reduced inflammatory brain lesions, improved immune cell profiles, and — unexpectedly — measurable improvement in cognitive processing speed.
“It was an improvement going from something bad to something better,” she has noted. That kind of improvement requires synaptic repair, not just symptom suppression.
The third trial, published in Lancet Neurology in 2016, was fully placebo-controlled across 16 sites. The cognitive improvement held against placebo.[4] It was no longer possible to attribute it to expectation.
She then built a mouse model specifically simulating menopause with chronic estrogen loss combined with midlife aging and showed the same pattern: cognitive deficits, hippocampal atrophy, and pathological changes in the brain that were reversed when treated with estriol or a pure ERβ agonist. The mechanism traced to glucose metabolism pathways in the hippocampus, involving a protein called enolase 1 that increased with cognitive decline and normalized with estriol treatment.[5]
The recognition that the same approach could help otherwise healthy menopausal women came from women around her including colleagues, patients, parents at school who described the same cognitive changes, getting dismissed by their doctors, and having no treatment designed specifically for what they were experiencing.
“These women have cognitive issues and there is no treatment designed for that,” she has said. “We have one that worked in MS.”
Understanding the ERα / ERβ Distinction
The table below illustrates why receptor selectivity matters — and why comparing estradiol and estriol on potency alone misses the point.
| Estradiol (E2) | Estriol (E3) | |
|---|---|---|
| Primary receptor | Estrogen receptor alpha (ERα) | Estrogen receptor beta (ERβ) |
| Dominant tissue distribution | Breast, uterus, reproductive organs | Brain (hippocampus, cortex), nervous system, colon |
| Cognitive evidence | Not shown to be specifically neuroprotective in major clinical trials[6] | Improved processing speed vs. placebo in MS trials; preclinical reversal of hippocampal atrophy in menopause model |
| Breast tissue stimulation | Strong ERα binding in breast tissue | Weak ERα binding; 40+ years of European use without increased breast cancer risk at therapeutic doses[7] |
| FDA approval (US) | Yes | No — compounded only |
| Use in Europe/Asia | Yes | Yes — oral and topical, 40+ years |
ERβ Beyond the Brain
The brain is where the most urgent need and the most rigorous evidence currently exist. But ERβ is not exclusive to the nervous system.
ERβ is the predominant estrogen receptor subtype in colon tissue, where it supports mucosal integrity and helps maintain gut barrier function.[10] Research in ERβ-deficient models shows disrupted tight-junction formation, altered gut microbiome composition, and increased susceptibility to inflammatory bowel conditions.[11] As understanding of the gut-brain axis deepens, particularly its role in mood, immunity, and systemic inflammation — the broader significance of ERβ activity during and after menopause is becoming clearer.
The brain is the primary focus of PearlPAK’s design. But receptor specificity may have protective relevance beyond cognition, in ways research is still mapping.
Who PearlPAK® Is Designed For
PearlPAK® is a compounded estriol and progesterone protocol developed from Dr. Voskuhl’s research and designed for women in perimenopause or menopause whose primary concern is cognitive health.
Consider discussing PearlPAK® with your provider if you:
- Experience brain fog, word-finding difficulty, or slowed processing as your primary symptom
- Have tried estradiol and found it did not address your cognitive symptoms
- Have a family history of cognitive decline and want a brain-targeted approach
- Are concerned about long-term estradiol use and want to understand a formulation with a different receptor profile and safety history
Who Should Not Use PearlPAK®
PearlPAK® is not appropriate for women with:
- A personal history of estrogen-sensitive breast cancer
- A history of blood clots or thromboembolism
- Untreated endometrial hyperplasia
- Known hypersensitivity to estriol or progesterone
- Severe or uncontrolled liver disease
As with any hormone therapy, a thorough clinical evaluation is required before starting treatment. A CleopatraRX provider will review your complete history before prescribing.
The Safety Profile of Oral Estriol
Oral estriol has been prescribed in Europe for more than 40 years. Long-term reviews have found no increased risk of breast cancer at therapeutic doses.[7]
Unlike oral estradiol, oral estriol does not appear to carry the same elevation in venous thromboembolism risk, though large prospective trials specific to oral estriol in menopause remain limited.[8]
In Dr. Voskuhl’s MS trials, participants received 8mg per day, double the PearlPAK® menopause dose of 2 to 4mg per day for up to two years, with no significant safety signals.[4]
One important clarification on the broader hormone therapy conversation: In November 2025, the FDA removed the black box warnings from all estrogen-containing hormone therapy products including the warnings related to breast cancer, cardiovascular disease, and dementia. This followed a comprehensive scientific review, an expert panel, and a public comment period.[9] The original warnings, added in 2003 following the Women’s Health Initiative, were based on a misinterpretation of data that has since been substantially reanalyzed. As the FDA’s own fact sheet noted, hormone therapy has been associated with a 50% reduction in heart attack risk, a 64% reduction in cognitive decline, and a 35% lower risk of Alzheimer’s in women who initiate treatment within ten years of menopause onset.[9]
The fear that drove women away from hormone therapy for two decades was not supported by the evidence as it now stands. Women deserve to make decisions based on accurate information — and that now includes knowing that the regulatory posture has changed.
How PearlPAK® Works
PearlPAK® is compounded by national PCAB-accredited pharmacies and shipped within the United States under valid prescription. The blister pack format mirrors the familiar structure of a birth control pack — designed to support compliance for women managing cognitive symptoms, where managing separate bottles and varying timing creates its own burden.
Dosing is individualized based on symptom profile. CleopatraRX clinical staff track outcomes using the Voskuhl Menopause Brain Fog Assessment at baseline and at 12-month intervals — a tool developed specifically because standard cognitive assessments like the MOCA were designed to detect Alzheimer’s disease, not the early domain-specific changes menopausal women actually experience.
What This Means for Your Care
Your doctor likely hasn’t mentioned estriol because the research is recent, the category is underfunded, and the path to FDA approval requires pharmaceutical investment that never materialized. That is not a reason to remain uninformed.
The science behind estriol’s cognitive mechanism has been in development for thirty years. The safety data has accumulated across two continents for forty years. What has been missing is the belief that women’s cognitive health deserves the same receptor-specific drug development that every other neurological condition receives.
Women deserve more than one option. Asking your doctor about estriol is a reasonable, evidence-supported question — and increasingly, it is one they will be prepared to answer.
CLINICIAN-GUIDED CARE
Ask the question.
Get an evidence-based answer.
A menopause-trained nurse reviews your symptoms, a physician confirms whether PearlPAK® fits, and cognitive improvement is tracked over time. Real care, start to finish.
Frequently Asked Questions
Is estriol weaker than estradiol?
Estriol binds less potently to estrogen receptor alpha (ERα), which is why it has historically been labeled “weaker.” But this comparison is measuring the wrong receptor for the wrong purpose. For cognitive protection, the relevant receptor is ERβ — which estriol binds preferentially and which is enriched in the brain regions most affected by menopausal cognitive decline. The question is not potency. It is specificity.
Why isn’t estriol FDA-approved in the United States?
FDA approval requires pharmaceutical industry sponsorship and large-scale clinical trials — both of which require significant financial investment. Because estriol cannot be patented in its natural form, there is limited commercial incentive for pharmaceutical companies to pursue approval. It remains available through compounding pharmacies under a valid prescription.
Is the estriol in PearlPAK® bioidentical?
Yes. The estriol used in PearlPAK® is bioidentical — molecularly identical to the estriol your body naturally produces.
Can estriol and estradiol be used together systemically?
Combining systemic estrogens requires careful clinical oversight and is not standard practice. If you are currently on estradiol and interested in transitioning to or adding estriol, this should be managed through a provider familiar with both therapies. A CleopatraRX provider can review your current regimen and discuss whether a transition makes sense for your symptom goals.
Does estriol help with hot flashes and sleep, or only cognition?
Both. Oral estriol addresses a range of menopausal symptoms including hot flashes, sleep disruption, and mood changes. PearlPAK® was designed with cognition as the primary clinical goal, but women on the protocol typically report improvement across multiple symptom domains.
References
[1] Mosconi L, et al. Perimenopause and emergence of an Alzheimer’s bioenergetic risk profile in brain and cognition. PLOS ONE. 2017;12(10):e0185926.
[2] Voskuhl RR, Wang H. Multiple sclerosis, pregnancy, and estriol. Curr Opin Neurol. 2002;15(3):293–297.
[3] Spence RD, et al. Neuroprotection mediated through estrogen receptor-α in astrocytes. Proc Natl Acad Sci USA. 2011;108(21):8867–8872.
[4] Voskuhl RR, et al. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(1):35–46. PubMed
[5] Itoh N, Itoh Y, Meyer CE, et al. Estrogen receptor beta in astrocytes modulates cognitive function in mid-age female mice. Nat Commun. 2023;14:6044.
[6] Andy C, et al. Systematic review and meta-analysis of the effects of menopause hormone therapy on cognition. Front Endocrinol. 2024;15:1350318.
[7] Head KA. Estriol: safety and efficacy. Altern Med Rev. 1998;3(2):101–113. Also: Lauritzen C. Results of a 5-year prospective study of estriol succinate treatment in climacteric patients. Maturitas. 1987;9(3):259–274.
[8] Canonico M, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2007;115(7):840–845.
[9] U.S. Department of Health and Human Services. Fact Sheet: FDA Initiates Removal of “Black Box” Warnings from Menopausal Hormone Replacement Therapy Products. November 10, 2025. hhs.gov.
[10] Looijer-van Langen M, et al. Estrogen receptor-β signaling modulates epithelial barrier function. Am J Physiol Gastrointest Liver Physiol. 2011;300(4):G621–G626.
[11] Guo T, et al. Estrogen receptor β deficiency impairs gut microbiota: a possible mechanism of IBD-induced anxiety-like behavior. Microbiome. 2022;10:160.
PearlPAK® is a prescription product. This article is for informational purposes and does not constitute medical advice. Results may vary. PearlPAK® is available in select US states — see cleopatrarx.com for current availability.